November is Pancreatic Cancer Awareness Month: Who can benefit from Screening?

November 17, 2017

 

 

Please note this article was originally published on the Sharsheret website, a national not-for-profit organization supporting young Jewish women and their families facing breast cancer. You can learn more about this wonderful organization here

 

November is Pancreatic Cancer Awareness Month, and what better time is there to discuss screening for Pancreatic Cancer? Around 53,000 people are expected to be diagnosed in the USA this year, with about 43,000 expected deaths from Pancreatic Cancer. We have not quite made the same progress with Pancreatic Cancer as we have with Colon and Rectal cancers, but trying to identify those individuals that may benefit from screening and early intervention remains a strong focus for many doctors today.

 

As is the case with many cancers including Breast Cancer, prevention and early detection are key. This would include screening programs for healthy individuals, as well as highlighting those patients who may be at elevated risk for development of the cancers, either due to a personal or family history of the cancer, or a genetic predisposition.

 

A problem we encounter with pancreatic cancer is that there are no guidelines for screening healthy patients like we have for breast or colon cancer. In 2016 the US Preventive Services Task Force concluded that there is not enough data to support national screening for all individuals. However, patients at elevated risk may benefit from screening strategies as outlined in multiple research studies. In particular, patients with a family history of pancreatic cancer or a genetic syndrome, of which BRCA positivity is one of those syndromes noted, would benefit from a screening strategy.

 

Pancreatic Cancer risks in our Breast Cancer patients in general are difficult to assess. There is no strong data to support a link between Breast and Pancreatic cancers, outside of specific genetic syndromes. For BRCA1 and BRCA2 carriers, the estimated lifetime risk of pancreatic cancer development is ~1% for BRCA1 carriers, which is similar to the general population, but is significantly elevated to ~5% for BRCA2 carriers. Based on these statistics, there are some doctors who advocate for screening BRCA2 carriers given the high lifetime risk.

 

Screening includes:

  • checking a blood test for a tumor marker called CA 19-9

  • MRI of the pancreas

  • And/or Endoscopic Ultrasound (an Endoscopy that uses internal ultrasound)

 

When to begin screening is an evolving topic. A recent study advocates for screening in general to begin at Age 50, and to continue every 3 years unless otherwise warranted by the exam findings. I do counsel my patients with a family history of pancreatic cancer to consider earlier screening at least 10 years earlier than that age at which their relative was diagnosed. Although there is no consensus guideline at this time, this has become one of the reasonable screening strategies.

 

The goal of screening is to identify and treat early cancers, or find early changes that may be intervened upon before cancer even develops. We want to identify those early cancers that can be surgically removed and cured, because late stage diagnosis is difficult to treat and is associated with poorer outcomes.

 

In summary, for patients with a family history of pancreatic cancer or BRCA mutations, strategies exist for Pancreatic Cancer screening, and I would encourage those patients to speak with their genetic counselors or gastroenterologists. In this fashion we hope to identify those patients with early abnormalities, or those individuals which may benefit from more aggressive monitoring in order to win the fight against pancreatic cancer.

 

References:

 

https://seer.cancer.gov/statfacts/

 

Ferrone CR, Levine DA, Tang LH, Allen PJ, Jarnagin W, Brennan MF, Offit K, Robson ME. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol. 2009;27(3):433.

 

Das KK, Early D. Pancreatic Cancer Screening.Curr Treat Options Gastroenterol. 2017 Sep 6.

 

Bartsch DK, Slater EP, Carrato A, eta l. Refinement of screening for familial pancreatic cancer.

Gut. 2016 Aug;65(8):1314-21.

 

DISCLAIMER: Please note that this blog is intended for Informational Use only and is not intended to replace personal evaluation and treatment by a medical provider. The information provided on this website is not intended as substitute for medical advice or treatment. Please consult your doctor for any information related to your personal care. 

Please reload

Recent Posts

Please reload

Archive

Please reload

Tags

Phone (972) 867-0019

STUART AKERMAN, MD

  • gi Plano, gi Dallas, colonoscopy
  • gi Plano, gi Dallas, colonoscopy
  • gi Plano, gi Dallas, colonoscopy

Board Certified Gastroenterologist

Fax (972) 867-7785

3242 Preston Road, Suite 200, Plano, TX 75093

Office Hours available Monday - Friday 8:30am - 4:30pm except Holidays

This website complies with Texas Medical Board Requirements. It was reviewed and Approved by Health Care Legal Counsel. It meets Regulatory Requirements and Is Not Intended to Be  Medical Advice.